PJCG2 Antibody

What is PLCG2 and why is it important in immunological research?

PLCG2 (Phospholipase C gamma 2) is a protein encoded by the PLCG2 gene in humans, also known as PLC-gamma-2, PLC-IV, FCAS3, and APLAID. It has a molecular mass of approximately 147.9 kilodaltons . PLCG2 plays a crucial role in the adaptive immune system, particularly in B-cell receptor signaling, and is implicated in various immunodeficiency syndromes and autoimmune disorders. Its importance in research stems from its involvement in multiple inflammatory signaling pathways, including MAPK, NF-κB, and NFAT, which regulate immune cell activation and inflammatory responses . Understanding PLCG2 function provides insights into immune system regulation and the pathophysiology of conditions characterized by immune dysregulation.

What are the most common applications for PLCG2 antibodies in research?

PLCG2 antibodies are widely used in various research applications including:

• Western Blotting (WB): For detecting PLCG2 protein expression levels and phosphorylation status

• Immunohistochemistry (IHC): For visualizing PLCG2 distribution in tissue sections

• Flow Cytometry (FCM): For analyzing PLCG2 expression in specific cell populations

• Immunoprecipitation (IP): For isolating PLCG2 protein complexes

• Immunofluorescence (IF): For cellular localization studies

• ELISA: For quantitative measurement of PLCG2 levels

These applications are essential for investigating PLCG2's role in normal immune function and pathological conditions such as PLAID and APLAID syndromes, as well as autoimmune diseases and inflammatory disorders.

How should researchers select appropriate PLCG2 antibodies for specific experimental purposes?

Selecting the appropriate PLCG2 antibody depends on several critical factors:

• Application specificity: Different antibodies perform optimally in specific applications. For example, some antibodies work well for Western blotting but poorly for immunohistochemistry. Review validation data for your intended application .

• Epitope targeting: Consider whether you need an antibody targeting total PLCG2 or phospho-specific antibodies (e.g., phospho-Tyr759, phospho-Tyr1217) based on the signaling events you're investigating .

• Species reactivity: Ensure the antibody recognizes PLCG2 in your experimental species. Many antibodies react with human PLCG2, but cross-reactivity with mouse, rat, or other model organisms varies significantly .

• Antibody format: Consider whether you need unconjugated antibodies or those conjugated to specific tags (HRP, fluorophores, biotin) based on your detection method .

• Validation evidence: Review published citations and validation data that demonstrate the antibody's specificity and performance in conditions similar to your experimental setup.

What are the optimal protocols for using PLCG2 antibodies in Western blotting for phosphorylation studies?

When using PLCG2 antibodies for phosphorylation studies via Western blotting, researchers should consider the following optimized protocol:

• Sample preparation:

  • Harvest cells quickly and lyse in buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) to preserve phosphorylation status.

  • Maintain samples at 4°C throughout processing to minimize dephosphorylation.

• Gel electrophoresis and transfer:

  • Use 7-8% gels to achieve good resolution of the large 147.9 kDa PLCG2 protein .

  • Transfer to PVDF membrane at lower current for longer time to ensure complete transfer of large proteins.

• Antibody incubation:

  • Block with 5% BSA (not milk) in TBST as milk contains phosphatases that may reduce signal.

  • For phospho-specific antibodies (such as phospho-Tyr759 or phospho-Tyr1217), incubate overnight at 4°C with gentle rocking .

  • Use phospho-PLCG2 antibodies first, then strip and reprobe with total PLCG2 antibodies to normalize phosphorylation to total protein.

• Controls:

  • Include positive controls (cells stimulated with pervanadate or antigen receptor engagement)

  • Include negative controls (phosphatase-treated lysates or PLCG2 knockout cells) .

• Detection:

  • Use enhanced chemiluminescence with longer exposure times if necessary, as phospho-specific signals may be weaker than total protein signals.

How can researchers effectively optimize immunohistochemistry protocols with PLCG2 antibodies?

Optimizing immunohistochemistry protocols with PLCG2 antibodies requires attention to several key factors:

• Fixation and tissue processing:

  • For PLCG2 detection, 10% neutral buffered formalin fixation for 24 hours is generally recommended.

  • Overfixation may mask epitopes, particularly phosphorylation sites, requiring more rigorous antigen retrieval.

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is typically effective.

  • Test both methods to determine optimal conditions for your specific PLCG2 antibody.

• Blocking and antibody dilution:

  • Use 5-10% normal serum from the species in which the secondary antibody was raised.

  • Test a range of primary antibody dilutions (1:100 to 1:1000) to determine optimal concentration .

  • Incubate primary antibody overnight at 4°C to enhance specific binding.

• Detection system selection:

  • For tissues with low PLCG2 expression, amplification systems like tyramide signal amplification may improve detection.

  • For co-localization studies, consider fluorescent secondary antibodies with appropriate controls for autofluorescence.

• Validation controls:

  • Include positive control tissues (lymphoid tissues are generally high in PLCG2)

  • Use isotype controls and PLCG2 knockout or knockdown tissues as negative controls where available.

What are the key considerations for validating PLCG2 antibody specificity in experimental systems?

Validating PLCG2 antibody specificity is crucial for ensuring reliable experimental results. Key considerations include:

• Genetic knockout/knockdown validation:

  • The gold standard for antibody validation is testing in PLCG2 knockout or knockdown systems.

  • Compare signals between wild-type and PLCG2-deficient samples to confirm specificity .

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide to block specific binding.

  • Comparison of blocked versus unblocked antibody staining patterns can confirm epitope-specific binding.

• Multiple antibody validation:

  • Use multiple antibodies targeting different PLCG2 epitopes to confirm consistent protein detection.

  • Discrepancies between antibodies may indicate non-specific binding or cross-reactivity with related proteins (like PLCG1).

• Phospho-antibody validation:

  • For phospho-specific antibodies, treat samples with phosphatases to confirm the signal is phosphorylation-dependent.

  • Use stimulation conditions known to induce PLCG2 phosphorylation (e.g., B-cell receptor crosslinking) as positive controls .

• Mass spectrometry confirmation:

  • When possible, confirm antibody-detected proteins by immunoprecipitation followed by mass spectrometry analysis.

  • This approach verifies both target protein identity and potential cross-reactive proteins.

How can PLCG2 antibodies be used to study PLAID and APLAID syndromes?

PLCG2 antibodies are invaluable tools for studying PLAID (PLCγ2-associated antibody deficiency and immune dysregulation) and APLAID (Autoinflammation and PLCγ2-associated antibody deficiency and immune dysregulation) syndromes through multiple approaches:

• Functional characterization of PLCG2 variants:

  • Western blotting with phospho-specific antibodies can detect heightened PLCγ2 phosphorylation in cells expressing disease-causing variants compared to wild-type controls .

  • This approach helps confirm the gain-of-function nature of mutations such as D993Y and Leu845Ser identified in APLAID patients .

• Signaling pathway analysis:

  • PLCG2 antibodies can be used to assess downstream activation of MAPK, NF-κB, and NFAT signaling pathways in patient cells or transfected cell lines .

  • Comparing signaling activation in mutant versus wild-type conditions helps elucidate pathogenic mechanisms.

• Structural studies:

  • Immunoprecipitation with PLCG2 antibodies followed by interaction studies can reveal how mutations disrupt the interaction between catalytic and autoinhibitory domains, leading to PLCγ2 autoactivation .

  • This approach helped demonstrate how the D993Y variant impairs PLCγ2 autoinhibition .

• Immunophenotyping correlations:

  • Combining flow cytometry for immune cell populations with Western blotting for PLCG2 expression/activation can reveal relationships between PLCG2 dysregulation and abnormal immune cell distributions in patients .

  • This approach identified severely reduced myeloid dendritic cells in an APLAID patient with the novel Leu845Ser mutation .

What techniques combine PLCG2 antibodies with single-cell analysis for studying immune dysregulation?

Integrating PLCG2 antibody-based detection with single-cell analysis techniques provides powerful insights into immune dysregulation:

• Single-cell Western blotting:

  • This emerging technique allows PLCG2 protein level and phosphorylation status to be assessed in individual cells.

  • By combining with cell surface markers, researchers can correlate PLCG2 activation with specific immune cell subsets.

• Mass cytometry (CyTOF) with phospho-PLCG2 antibodies:

  • Metal-conjugated antibodies against total and phosphorylated PLCG2 can be incorporated into CyTOF panels.

  • This approach enables simultaneous assessment of PLCG2 activation alongside dozens of other markers in single cells, revealing how PLCG2 activation differs across immune cell populations in disease contexts .

• Single-cell RNA-seq with protein detection:

  • Technologies like CITE-seq combine transcriptome analysis with antibody-based protein detection.

  • This approach can correlate PLCG2 protein levels with transcriptional changes at single-cell resolution.

  • Single-cell RNA sequencing revealed exacerbated inflammatory responses in peripheral blood mononuclear cells from an APLAID patient with the D993Y variant .

• Phospho-flow cytometry:

  • Phospho-specific PLCG2 antibodies in flow cytometry can track activation dynamics in response to stimuli across immune cell subsets.

  • This technique has revealed how PLCG2 mutations alter activation thresholds in different cell types, contributing to the complex phenotypes in PLAID/APLAID syndromes .

• Imaging mass cytometry:

  • This technique combines the high-parameter capabilities of mass cytometry with spatial resolution.

  • Using metal-tagged PLCG2 antibodies, researchers can visualize PLCG2 expression and activation patterns within tissue microenvironments.

How do researchers use PLCG2 antibodies to investigate the role of PLCG2 in autoimmune diseases?

PLCG2 antibodies are essential tools for investigating the role of PLCG2 in autoimmune diseases through several approaches:

• Comparative phosphorylation analysis:

  • Western blotting with phospho-specific PLCG2 antibodies allows researchers to compare activation levels between patient and healthy control samples.

  • Elevated PLCG2 phosphorylation has been observed in conditions like type 1 diabetes, which shares autoimmune etiology with PLCG2-related disorders .

• Immune complex analysis:

  • Co-immunoprecipitation with PLCG2 antibodies followed by mass spectrometry can identify abnormal protein interactions in autoimmune conditions.

  • This approach has helped elucidate how PLCG2 hyperactivation leads to dysregulated immune complex formation and processing.

• Tissue-specific expression studies:

  • Immunohistochemistry with PLCG2 antibodies in affected tissues (e.g., pancreatic islets in type 1 diabetes, synovial tissue in rheumatoid arthritis) reveals localization and activation patterns.

  • This helps correlate PLCG2 activity with tissue damage and inflammatory infiltrates.

• Therapeutic response monitoring:

  • PLCG2 antibodies enable assessment of treatment effects on PLCG2 signaling.

  • Monitoring PLCG2 phosphorylation before and after intervention provides mechanistic insights into therapeutic responses in autoimmune conditions.

• Genetic variant functional characterization:

  • For patients with suspected PLCG2 variants, antibody-based functional assays help determine whether variants are pathogenic.

  • This approach has expanded understanding of how common genetic variants in PLCG2 contribute to type 1 diabetes and venous thromboembolism .

What are common pitfalls when working with PLCG2 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with PLCG2 antibodies:

• Non-specific binding and background issues:

  • Problem: High background or multiple bands in Western blotting.

  • Solution: Optimize blocking (try 5% BSA instead of milk), increase washing stringency, and titrate antibody concentration. For phospho-antibodies, ensure phosphatase inhibitors are fresh and active .

• Inconsistent phospho-antibody signals:

  • Problem: Variable phospho-PLCG2 detection between experiments.

  • Solution: Standardize cell stimulation protocols, minimize time between cell harvesting and lysis, maintain consistent temperature during processing, and include positive control samples (pervanadate-treated cells) .

• Epitope masking in fixed tissues:

  • Problem: Poor signal in immunohistochemistry despite positive Western blot results.

  • Solution: Test different antigen retrieval methods (heat-induced vs. enzymatic), adjust retrieval time and pH, and consider testing antibodies raised against different epitopes .

• Cross-reactivity with PLCG1:

  • Problem: Antibodies recognizing both PLCG1 and PLCG2 due to sequence homology.

  • Solution: Select antibodies specifically validated against both proteins, use PLCG2-knockout cells as negative controls, and confirm specificity with siRNA knockdown experiments .

• Limited detection of native conformation:

  • Problem: Antibodies that work for denatured protein detection fail in native applications.

  • Solution: Select antibodies specifically validated for native applications (IP, flow cytometry), or use multiple antibodies targeting different epitopes.

How can researchers interpret conflicting results from different PLCG2 antibodies?

When faced with conflicting results from different PLCG2 antibodies, researchers should consider the following interpretation and troubleshooting approaches:

• Epitope accessibility differences:

  • Different antibodies target distinct epitopes that may be differentially accessible depending on protein conformation, fixation methods, or interaction with other proteins.

  • Solution: Map the epitopes of each antibody and consider whether certain domains might be masked in specific experimental conditions.

• Phosphorylation-dependent epitope recognition:

  • Some antibodies may have reduced binding when nearby amino acids are phosphorylated, even if they're not marketed as phospho-specific.

  • Solution: Test antibody binding after phosphatase treatment to determine if phosphorylation status affects recognition.

• Isoform-specific detection:

  • PLCG2 can exist in multiple isoforms due to alternative splicing or post-translational modifications.

  • Solution: Verify which isoforms each antibody detects and determine which isoforms are expressed in your experimental system.

• Validation hierarchy approach:

  • Establish a hierarchical validation approach using genetic controls (PLCG2 knockout/knockdown), peptide competition, and orthogonal detection methods.

  • Results that are consistent across multiple validation methods should be given greater weight than isolated findings with a single antibody.

• Batch and lot variation:

  • Manufacturing inconsistencies between antibody lots can lead to variability.

  • Solution: Record lot numbers, maintain consistent sourcing when possible, and revalidate new lots against previous results.

What advanced strategies can improve detection of low-abundance PLCG2 phosphorylation events?

Detecting low-abundance PLCG2 phosphorylation events requires specialized approaches:

• Phosphoprotein enrichment techniques:

  • Phosphopeptide enrichment: Use titanium dioxide or immobilized metal affinity chromatography (IMAC) to enrich phosphopeptides before mass spectrometry analysis.

  • Phosphoprotein immunoprecipitation: Perform initial immunoprecipitation with total PLCG2 antibodies followed by Western blotting with phospho-specific antibodies to concentrate the target protein .

• Signal amplification methods:

  • Enhanced chemiluminescence (ECL) substrates: Use high-sensitivity detection reagents specifically designed for low-abundance phosphoproteins.

  • Tyramide signal amplification (TSA): For immunohistochemistry and immunofluorescence, TSA can amplify weak signals by depositing additional reporter molecules at the site of antibody binding.

• Proximity ligation assay (PLA):

  • This technique can detect protein interactions and modifications with single-molecule sensitivity.

  • Using antibodies against PLCG2 and phosphotyrosine in combination, PLA can visualize low-level phosphorylation events as distinct puncta under fluorescence microscopy.

• Targeted mass spectrometry approaches:

  • Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) mass spectrometry can detect specific PLCG2 phosphopeptides with high sensitivity.

  • These approaches can be used to quantify phosphorylation at specific sites (Tyr759, Tyr1217) that are challenging to detect by antibody-based methods alone .

• Genetic engineering approaches:

  • Overexpression systems: When studying specific PLCG2 variants, controlled overexpression can enhance detection of phosphorylation events.

  • CRISPR knock-in of tagged PLCG2: Introducing epitope tags at the endogenous PLCG2 locus can facilitate enrichment and detection while maintaining physiological expression levels .

How are PLCG2 antibodies being used in single-cell transcriptomics integration studies?

Researchers are developing innovative approaches to integrate PLCG2 antibody-based protein detection with single-cell transcriptomics:

• CITE-seq with PLCG2 antibodies:

  • Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) using oligonucleotide-tagged PLCG2 antibodies allows simultaneous measurement of PLCG2 protein levels and transcriptome-wide gene expression.

  • This approach has revealed relationships between PLCG2 protein expression and transcriptional states in immune cells from patients with PLAID/APLAID syndromes .

• Trajectory analysis with protein data:

  • By incorporating PLCG2 protein measurements into single-cell trajectory analyses, researchers can map how PLCG2 expression and activation change during immune cell differentiation and activation.

  • Single-cell sequencing has revealed altered proportions of different cell types in peripheral blood of APLAID patients, providing insights into disease pathophysiology .

• Multi-modal data integration frameworks:

  • Computational methods that integrate protein measurements (including PLCG2) with transcriptomic data provide higher-resolution cell type classifications.

  • These approaches have identified previously uncharacterized immune cell states associated with PLCG2 hyperactivation in inflammatory disorders.

• Spatial transcriptomics with protein detection:

  • Emerging spatial omics platforms combine transcriptome profiling with antibody-based protein detection in tissue sections.

  • Adding PLCG2 antibodies to these panels helps map the spatial distribution of PLCG2-expressing cells relative to inflammatory foci.

• Temporal analysis of PLCG2 activation:

  • Time-course experiments combining antibody-based PLCG2 phosphorylation detection with transcriptional profiling reveal the kinetics of PLCG2-dependent gene expression changes.

  • This approach has identified early and late transcriptional responses to PLCG2 activation in models of autoinflammatory disease.

What role do PLCG2 antibodies play in studying novel therapeutic approaches for PLCG2-associated disorders?

PLCG2 antibodies serve crucial functions in developing and evaluating novel therapeutic approaches for PLCG2-associated disorders:

• Target engagement studies:

  • For small molecule inhibitors targeting PLCG2, antibodies help confirm direct binding and measure inhibition of phosphorylation at specific sites.

  • This approach has been essential for characterizing compounds that selectively inhibit hyperactive PLCG2 variants while sparing normal function.

• Therapeutic window assessment:

  • By measuring PLCG2 phosphorylation in patient-derived cells versus healthy controls, researchers can determine whether a therapeutic intervention normalizes PLCG2 activity without causing immunosuppression.

  • Western blotting with phospho-specific antibodies has been used to establish dose-response relationships for potential therapeutics .

• Cell-type specific drug responses:

  • Flow cytometry with phospho-PLCG2 antibodies enables measurement of drug effects across different immune cell populations.

  • This approach has revealed that therapeutic candidates may have variable efficacy depending on cell type, helping to predict clinical responses.

• Biomarker development:

  • PLCG2 phosphorylation measured by antibody-based assays serves as a potential biomarker for patient stratification and treatment response monitoring.

  • Standardized phospho-PLCG2 assays are being developed to support clinical trials for targeted therapies.

• Gene therapy validation:

  • For genetic approaches aiming to correct PLCG2 mutations, antibodies allow verification of proper protein expression and normalization of signaling.

  • Immunoblotting and immunostaining have confirmed successful gene editing of pathogenic PLCG2 variants in preclinical models.

How can researchers apply PLCG2 antibodies in studying the intersection of PLCG2 signaling with other immune pathways?

Investigating the intersection of PLCG2 signaling with other immune pathways requires sophisticated applications of PLCG2 antibodies:

• Multiplex phosphoprotein analysis:

  • Simultaneous detection of PLCG2 phosphorylation alongside other signaling molecules (SYK, BTK, ERK, NF-κB) provides a systems-level view of pathway crosstalk.

  • Multiplexed Western blotting or phospho-flow cytometry with carefully validated antibody panels can map signaling networks altered in disease states .

• Co-immunoprecipitation network mapping:

  • Using PLCG2 antibodies for immunoprecipitation followed by mass spectrometry identifies interaction partners and how these change in disease states or upon stimulation.

  • This approach has revealed how PLCG2 mutations alter interactions with regulatory proteins, contributing to pathway dysregulation .

• Proximity labeling approaches:

  • PLCG2 fusion proteins with BioID or APEX2 enable proximity-dependent labeling of the PLCG2 interactome.

  • Antibodies against PLCG2 help validate these approaches and confirm appropriate localization and function of fusion proteins.

• Integrated signalome profiling:

  • Combining antibody-based detection of PLCG2 activation with broad phosphoproteomic profiling reveals downstream effectors and feedback mechanisms.

  • This approach has identified previously unrecognized connections between PLCG2 and other inflammatory pathways in APLAID syndrome .

• Spatial analysis of signaling microenvironments:

  • Multiplex immunofluorescence with PLCG2 and other pathway antibodies maps the spatial organization of signaling in tissues.

  • This technique has revealed how PLCG2-hyperactive cells influence neighboring cells through altered cytokine production and contact-dependent mechanisms.